

ATTACH #16

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	09/205,096
Filing Date	12/03/98
First Named Inventor	Daniel DRACMAN et al
Group Art	1633
Examiner Name	E. Sorbello
Attorney Docket Number	01107.82665

Total Number of Pages in This Submission

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Response <input checked="" type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Tabs A-O
---	--	--

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT


Firm or Individual name	Banner & Witcoff, Ltd., 1001 G Street, N.W., Washington, DC 20001-4597
Signature	<i>Michelle Thompson</i>
Date	October 15, 2001

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date:

Typed or printed name			
Signature		Date	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



TECHNICAL 1600/2000

OCT 17 2001

RECEIVED

1613 (UB)
10/17/01
PATENT

RECEIVED

OCT 17 2001

TECH CENTER 1600/2900


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Daniel Drachman, et al.

Serial No. 09/205,096

Filing Date: December 3, 1998



)
) Group Art Unit: 1633
)
) Examiner: E. Sorbello
)
) Docket No. 01107.77737

For: **TARGETING ANTIGEN-SPECIFIC CELLS FOR SPECIFIC
IMMUNOTHERAPY OF AUTOIMMUNE DISEASE**

**AMENDMENT AND
RESPONSE TO FINAL OFFICE ACTION**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This amendment is filed in response to the Office Action mailed July 13, 2001. Claims 41-67 are currently pending and are rejected. We believe no fees are due to make this amendment timely filed. If any fee is due, please charge our Deposit Account No. 19-0733.

IN THE CLAIMS

Please amend claims 54 and 58.

54. (Amended) Antigen presenting cells of an auto-immune disease patient which are transduced or transfected with a polynucleotide encoding a protein comprising all or a portion of

Max
et al.
11/12/01

10